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It is known that Alzheimer’s disease (AD) presents at an early age in people with Down syndrome (DS).
The trisomy 21 in DS provides an opportunity to study the effect of duplicated genes in AD. APP and
BACE2 are 2 genes located in chromosome 21 and related to AD. We looked into our cohort of 67 DS cases
with dementia for the effect of BACE2 variants in age of onset of dementia. Of the 83 single-nucleotide
polymorphisms (SNPs), 6 were associated with age of onset and another 8 SNPs were borderline asso-
ciated. Our ﬁnding also replicated a previous study showing association of rs2252576 with AD.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Down syndrome (DS), or trisomy 21, is caused by an extra copy
of chromosome 21. The prevalence of Alzheimer’s disease (AD) and
dementia in the general population and in people with DS in-
creases with age (Margallo-Lana et al., 2007; Murray et al., 2013).
In DS, the densities of senile plaques and neuroﬁbrillary tangles
increase with aging but can occur in people as young as 37 years
(Mann et al., 1990). Despite the pathologic changes, the age of
onset (AOO) of dementia varies (Prasher and Krishnan, 1993),
suggesting that factors other than trisomy of APP in DS are
important.
The study of genetic roles in AD contributes to understanding
dementia in DS. We have previously shown that in DS poly-
morphisms in PICALM and APOE are associated with AOO of de-
mentia, and there is a nonsigniﬁcant trend in risk allele loadingr Neuroscience, UCL Institute
Square, London WC1N 3BG,
4017.
Inc. Open access under CC BY license.derived from AD meta-analysis (Jones et al., 2013). Conversely,
study of dementia in DS, particularly the role of trisomy in chro-
mosome 21, allows us to understand mechanisms of AD. APP and
BACE2 are both located on chromosome 21. We previously showed
that haplotypes in BACE2 are associated with AD (Myllykangas
et al., 2005). However, other studies suggested that BACE2 might
not play a signiﬁcant role in AD (Cheon et al., 2008; Holler et al.,
2012). We attempted to look into the role of BACE2 in AOO of
dementia in DS.2. Methods
The cohort, genotyping and quality control measures were as
previously reported (Jones et al., 2013). In brief, this comprised of
94 samples from 2 clinical trials (DOWNSLIT [http://public.ukcrn.
org.uk/search/StudyDetail.aspx?StudyID¼5927] and MEADOWS;
Hanney et al., 2012) and 64 brain samples from various brain banks
(details in Supplementary Data). For samples from clinical trials,
AOO of dementia was as recorded by the trial psychiatrist. Mean
duration of dementia before death in people with DS is approxi-
mately 5 years, and AOO for the autopsy cohort was deﬁned as the
age of death minus 5, which assumes all individuals over the age of
34 years had dementia before death.
Fig. 1. Plot of 6 SNPs with signiﬁcant association with AOO around BACE2. Median age of onset of dementia according to genotype. 0 ¼ homozygous major allele, 1 ¼ 2 major alleles
and 1 minor allele, 2 ¼ 1 major allele and 2 minor alleles, and 3 ¼ homozygous trisomy of minor allele. (A) rs9981478 C/T (minor/major); (B) rs7510366 T/C; (C) rs2252576 T/C; (D)
rs2837990 A/G; (E) rs7281733 A/G; and (F) rs6517664 T/C. Abbreviations: AOO, age of onset; SNP, single-nucleotide polymorphism.
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available DNeasy Blood and Tissue kit (Qiagen, UK). Genotyping
was done in the UCL Genomics Centre using HumanOmniExpress-
12v1_H beadchips. After the initial quality control check, 129 samplesremained (males: 72; females: 57). Of these, only 70 samples were
classiﬁed as having dementia and only 67 samples were AOO docu-
mented. This formed the cohort for current analysis and was as pre-
viously reported (Jones et al., 2013) (details in Supplementary Table 1).
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GenomeStudio (Illumina, San Diego, CA, USA) is based on diploid
status. Manual recluster for polyploidy-genotyping was performed
using GenomeStudio module v1.9.4 (http://res.illumina.com/
documents/products/technotes/technote_genomestudio_polyploid_
genotyping.pdf).All single-nucleotidepolymorphisms(SNPs) (n¼85)
within theBACE2 locusþ/ 50kbwere reclustered and thegenotypes
of SNPs were exported for further analysis. The minor allele was
evaluated to be the risk allele.
Regression analysis was performed in R v2.15.2 (R Development
Core Team, 2008). AOO regression was analyzed using an additive
model. Components 1 and 2 in PLINK, multidimensional scaling
(Purcell et al., 2007) were used as covariates, in addition to gender
and the classiﬁcation of the sample as clinical or autopsy. A nominal
p value of 0.05 was used as a cutoff for nominal signiﬁcance.3. Results
The 67 cases (men:women ¼ 36:31) had average age of
55.6 years (standard deviation  7.3). There was a total of 85 SNPs
within 50 kb of BACE2 (chr21:42539728e42654461, hg19). Of
these, 2 SNPs were excluded because they were monomorphic
(Supplementary Table 1).
Among the 83 SNPs, 6 SNPs have a nominal signiﬁcance with
p < 0.05 and another 8 SNPs have p value between 0.05 and 0.1
(Fig. 1, Table 1, and Supplementary Table 1). All except 4 SNPs were
clustered within the exons 6e9 and the 30 region (Supplementary
Fig. 1), which fell within a haplotype block of Hapmap3 European
cohort (Supplementary Fig. 2). The most signiﬁcant SNP, rs7287133
is in linkage disequilibrium (LD) with some other signiﬁcant SNPs
and borderline signiﬁcant SNPs (Supplementary Fig. 1), suggesting
that the haplotype in this region is probably important for AD.4. Discussion
There are 2 major limitations in the present study. The ﬁrst one
is the small sample size and therefore limits the power to conclude
deﬁnitely the association. The second one comes from correction
for multiple testing. Multiple testing is performed for all SNPs
within BACE2.
Correction for multiple testing within high LD block can be
difﬁcult. Applying Bonferroni correction is too conservative and
leads to false negative results. HapMap Utah residents (Centre
d0Etude du Polymorphisme Humain) with Northern and Western
European ancestry and Toscani in Italy (CEU þ TSI) data suggest theTable 1
SNPs with signiﬁcant association with AOO around BACE2
SNP Position Minor allele Nominal
p value
Nominal signiﬁcant rs9981478 42558694 C 0.0316
rs7510366 42581927 T 0.0274
rs2252576 42615293 T 0.0315
rs2837990 42620149 A 0.0394
rs7281733 42655515 A 0.0258
rs6517664 42704983 T 0.0376
Borderline signiﬁcant rs6517656 42583738 A 0.0866
rs2837994 42624124 A 0.091
rs11702001 42627969 A 0.0722
rs8133778 42642038 A 0.075
rs2838003 42649357 C 0.0774
rs2006737 42657187 G 0.0793
rs1072869 42657548 C 0.0607
rs9984207 42662259 T 0.0601
Key: AOO, age of onset; SNP, single-nucleotide polymorphism.BACE2 region falls into 5 major blocks (Supplementary Fig. 2). Most
of the nominal and borderline signiﬁcant SNPs cluster around the
exon 6 to the 30 untranslated region (30UTR), and Hapmap data
suggest that this is a block of high LD. If we apply the correction
according to the number of haplotype blocks, the corrected p value
of signiﬁcance should be 0.05/5 ¼ 0.01. Our SNPs will fall out of
signiﬁcance but are still borderline signiﬁcant.
Another theoretical correction has to be made for testing
multiple genes. Our previous report suggested PICALM and APOE as
risk factors for early onset of dementia in DS (Jones et al., 2013). In
the previous study, we tested 157 SNPs in 74 gene regions (35
SNPs in 15 genes are among the APOE block). The present study is
focused on BACE2 with the genotype manual reclustered for tri-
somy as mentioned in section 2, and can be viewed as a compli-
mentary study to previous study. Straight multiple testing
correction will result in the currently studied SNPs becoming
insigniﬁcant.
The current data on DS support our group’s previous report
(Myllykangas et al., 2005) of association of haplotypes in BACE2
with AD. In a study by Myllykangas, we found rs2252576 (minor T
allele) and haplotypes including this SNP were associated with AD
in Finns and Americans. Our current AOO regression data also show
that rs2252576-T allele possibly associates with an earlier age of
onset of dementia (slope ¼ 2.4 year/per T allele) in DS.
The role of BACE2 in AD has been controversial. BACE2 expres-
sion was not found to be increased in adult DS brain (Cheon et al.,
2008). However, Lockstone et al. (2007) found increased BACE2
expression in adult DS brain. Holler et al. (2012) reported an in-
crease in BACE2 messenger RNA in DS that did not translate into
increased BACE2 protein levels and activities in DS, despite in-
creases in other neurodegenerative diseases. However, over-
expression of BACE2was found to decrease amyloid beta production
in neuronal cultures (Abdul-Hay et al., 2012; Sun et al., 2006).
Our SNPs with nominal and borderline signiﬁcance were
observedmainly around the 30 end and not in the 50UTR region. This
is in congruent with a negative association of SNPs in 50-ﬂanking
region done in an Asian population of AD (Yu and Jia, 2009).
Association of SNPs in BACE2 with AD is not found in the
recent mega meta-analyses of genome-wide association study
(Hollingworth et al., 2011; Lambert et al., 2013; Naj et al., 2011). The
discrepancy may be related to our study population being all tri-
somy 21, including APP.
We postulate that with duplication of APP, the increased gene
dosage contributes a greater role in the pathogenesis of AD,
compared with other AD cases without APP duplication. Subse-
quently, gene products, for example from BACE2, that interact with
the APP will play a greater role in dementia pathogenesis among
trisomy cases than in AD subjects with diploid APP. Expression of
BACE2 was reported to be increased in adult brain with DS
(Lockstone et al., 2007). The upregulation of the APP-related system
in DSmay explainwhy BACE2 SNPs are not found to be associated in
general AD genome-wide association study, but are suggestive
when the dementia cohort is made up of APP trisomy, as in the
present study.
Our data on rs2252576, rs2837990, and rs7281733 suggest that
the minor alleles may predispose to early onset of dementia,
implying these variants and the functional alteration caused are
pathogenic. The oppositewas foundwith rs7510366 and rs6517664.
Pathogenicity can be because of variants enhancing a pathogenic
role of the protein or diminishing a protective role. Hence, other
studies are needed to determine the functional role of BACE2.
In summary, we ﬁnd variants in BACE2 that possibly affect the
AOO of dementia in DS, suggesting a potential role of BACE2 in AD
and DS. Dementia in DS can provide an important model to study
the role of APP and related genes in AD.
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